Belfast, United Kingdom

Tianbao Chen



Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2011-2013

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Tianbao Chen in Peptide Research

Introduction

Tianbao Chen is a notable inventor based in Belfast, GB. He has made significant contributions to the field of peptide research, holding a total of 3 patents. His work focuses on the development of peptides that exhibit selective actions on smooth muscle, which has important implications for cardiovascular health.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Peptides, compositions and uses thereof." This patent describes an N-terminal hexapeptide fragment of maximakinin, known as QUB 698.8. This peptide demonstrates potent tissue-selective actions on smooth muscle, showing a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle. It causes potent relaxation of arterial smooth muscle while inducing less potent contraction of ileal smooth muscle. The potential applications of this invention include the treatment of diseases of the cardiovascular system and the promotion of angiogenesis.

Career Highlights

Tianbao Chen is affiliated with The Queen's University of Belfast, where he conducts his research. His innovative work in peptide development has positioned him as a key figure in the scientific community, particularly in the area of cardiovascular treatments.

Collaborations

He collaborates with esteemed colleagues such as David Hirst and Martin O'Rourke, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Tianbao Chen's contributions to peptide research are significant, particularly in the context of cardiovascular health. His patents reflect a commitment to advancing medical science through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…